Navigation Links
PharmAthene to Host First Quarter 2008 Conference Call and Webcast on Tuesday, May 13, 2008
Date:5/6/2008

become the premier company worldwide specializing in the development and commercialization of therapeutic and prophylactic products for defense against biological and chemical threats. Since its inception, PharmAthene has pursued an acquisitive growth strategy focused on high priority, next generation biodefense products that the government has expressed a clear need and intent to procure. PharmAthene's portfolio currently includes five potential best- in-class biodefense medical countermeasures: Recombinant Protective Antigen (rPA) anthrax vaccine; Valortim(TM), an anthrax anti-toxin therapeutic which is being co-developed with Medarex; Protexia(R) a novel recombinant bioscavenger to prevent and treat organophosphorous nerve agent poisoning; RypVax(TM), a recombinant dual antigen plague vaccine; and finally, third generation rPA anthrax vaccine technology. For more information on PharmAthene, please visit http://www.PharmAthene.com.


'/>"/>
SOURCE PharmAthene, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
3. PharmAthene Named as Contractor in $13.9 Million Award Notice Published by the Department of Health and Human Services
4. Delaware Court Denies Motion by SIGA Technologies Seeking to Dismiss PharmAthenes Legal Action in Breach of Contract Lawsuit Against SIGA
5. PharmAthene to Present at the BIO CEO & Investor Conference 2008
6. PharmAthene Enhances Executive Leadership Team and Appoints Joan Fusco, Ph.D. Senior Vice President of Operations
7. PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008
8. PharmAthene to Present at the Cowen and Company 28th Annual Health Care Conference
9. PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia
10. PharmAthene to Delay Release of Full Year 2007 Financial Results
11. PharmAthene Year-End 2007 Earnings Conference Call and Webcast Scheduled for Monday, March 31, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... CIRTEC Medical Systems’ Board of Directors ... of CIRTEC. , “I am delighted to be ... noted Brian Highley. “The company has made great strides ... growth over the past two years. The goal now ... and expand the services Cirtec offers its medical device ...
(Date:9/16/2014)... Ky. , Sept. 16, 2014  LABSCO, ... technologies and products to hospitals, physician office laboratories ... that, effective October 1, 2014, it will serve ... specified hospital market segments and as a semi-exclusive ... the 48 contiguous United States ...
(Date:9/16/2014)... According to Jeff Howell, Partner of Nidea Corporate ... development in Downtown Toronto is expanding at a blistering ... storeys of new development last week (including three new ... the Toronto skyline for the foreseeable future in a ... new development. , As the Toronto city council met ...
(Date:9/15/2014)... 15, 2014 EnGeneIC, Ltd. , ... treatment of cancer through the targeted delivery of ... together with the Asbestos Disease Research Institute (ADRI), ... South Wales (NSW) Premier,s Award for Excellence in ... the hospitals that will be involved in the ...
Breaking Biology Technology:LABSCO Secures Alliance With Siemens Healthcare Diagnostics 2LABSCO Secures Alliance With Siemens Healthcare Diagnostics 3ITRA Global Reports Downtown Toronto Real Estate Development is in High Gear 2ITRA Global Reports Downtown Toronto Real Estate Development is in High Gear 3EnGeneIC Named a Recipient of the Cancer Institute NSW Premier's Award for Excellence in Translational Cancer Research 2EnGeneIC Named a Recipient of the Cancer Institute NSW Premier's Award for Excellence in Translational Cancer Research 3
... study, only 25 percent of online marketers track their ... at the Jupitermedias 2004 Search Engine Strategies Conference in ... who create pay-per-click campaigns set them up and let ... ,According to the study, active online marketers often track ...
... Inc., can continue to sell advertising to competitors of ... ads, a federal district court in Virginia has ruled. ... and lucrative part of Googles business. In the third ... came from keyword advertising, also called sponsored links. ...
... about using biomass and enzymes to produce hydrogen fuel, ... Badger AgVest in Lake Delton last Thursday. ... brought to the conference by the AgVest group, which ... doesn't make specific recommendations, AgVest tries to hook up ...
Cached Biology Technology:How to make pay-per-click ad campaigns pay off 2Google wins first battle in trademark war 2Investors hear about new agricultural technology 2
(Date:9/16/2014)... the "molecular brakes" that time the generation of important ... "hair cells" translate sound waves into electrical signals that ... sounds. If the arrangement of the cells is disordered, ... research will be published in The Journal of ... and Hey2 act as brakes to prevent hair cell ...
(Date:9/16/2014)... we inherit certain traits from our parents that are ... genes play out by taking certain drugs or better ... a team of researchers at the Boston University School ... epigenetics research. , Epigenetics regulates gene expression in ... proteins, which prevent permanent mutations or alterations within the ...
(Date:9/16/2014)... has its own bacterial identity. That,s the conclusion of ... who studied the genetic fingerprints of bacteria on 57 ... "This study demonstrates for the first time that host ... strategies possess very different microbial communities on their leaves," ... researcher in the UO,s Institute of Ecology and Evolution ...
Breaking Biology News(10 mins):Hey1 and Hey2 ensure inner ear 'hair cells' are made at the right time, in the right place 2Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 2Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 3Microbiome research shows each tree species has a unique bacterial identity 2
... The ongoing dance between a virus and ... human adenoviruses typically cause mild infections, recent reports have ... fatal, human infections. Researchers from the Massachusetts ... for Public Health, School of Systems Biology, George Mason ...
... balls that can zap pain and lung tumors to ... physicians will present the latest research on cutting-edge treatments ... Meeting April 13󈝾 at the Ernest N. Morial Convention ... the theme "IR Reaching Out" and delivers education, resources ...
... have identified a new potential therapeutic target for lowering ... to statins. Scientists in the lab of ... action of a gene responsible for transporting a protein ... remove cholesterol from the blood in mice. Trapping the ...
Cached Biology News:Society of Interventional Radiology: 38th Annual Scientific Meeting 2U-M researchers find new way to clear cholesterol from the blood 2
... in-house demand is causing shortages in your ... This can cause unwanted distractions, problems and ... royalties for your hard work and endeavour! ... build it up,and market it internationally. We ...
Topoisomerase I...
...
... vaccinia virus is a type I eukaryotic ... superhelical turns (also called right- and left-handed ... of the reaction is a covalently closed, ... superhelical turns. DNA Topoisomerase I does not ...
Biology Products: